GET DAILY SIGNALSEmergent BioSolutions (EBS) Q3 2026 Results Prompt Guidance Adjustment
Key Takeaways
- Third quarter 2026 revenue came in at roughly $110 million, within management's $110–$130 million guidance range but below the analyst consensus of about $123 million.
- Adjusted EBITDA turned negative at approximately $5 million, with an adjusted gross margin of 28%.
- Management lowered full-year 2026 guidance to $600–$645 million in revenue and $110–$140 million in adjusted EBITDA, reflecting softer naloxone pricing and MCM delivery timing.
- The company continued to strengthen its balance sheet, cutting gross debt to $514 million and holding net leverage steady at 2.4 times trailing adjusted EBITDA.
- An August restructuring program is expected to deliver roughly $40 million in annualized savings, with most of the benefit materializing in 2027.
- Shares moved lower following the release, as results came in below Wall Street's top-line expectations.
- For more context, explore Emergent BioSolutions' Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Investors seeking additional data-driven signals can also explore Trending AI Robots for automated market analysis.
Putting the Quarter in Context
Emergent BioSolutions (EBS), known primarily for its NARCAN nasal spray and government medical countermeasures contracts, released third quarter 2026 results on November 2, 2026. The period followed the expected pattern of a step-down after accelerated U.S. government deliveries earlier in the year, alongside continued pressure from competition in the naloxone space. From what I see, the results offer a useful checkpoint on the company's multi-year effort to reduce debt and stabilize margins. This matters because the firm needs to defend its naloxone position against generics while maintaining reliable wins on medical countermeasures from government buyers.
What the Numbers Showed
Revenue for the quarter totaled approximately $110 million. That figure fell inside the company's prior guidance of $110–$130 million yet came in below the consensus estimate near $123 million and well below the $231 million posted a year earlier. The drop stemmed mainly from the timing of MCM deliveries that had been accelerated into the second quarter, plus softer naloxone results.
Adjusted EBITDA landed at negative $5 million, while adjusted gross margin reached 28%, weighed down by product mix and competitive dynamics. Year-to-date revenue stood at $500 million, supported by adjusted EBITDA of $128 million (a 25% margin) and operating cash flow of $122 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Management revised full-year 2026 guidance downward to revenue of $600–$645 million (from $645–$675 million) and adjusted EBITDA of $110–$140 million (from $130–$150 million). On the balance sheet, cash reached $176 million with total liquidity at $226 million. Gross debt declined to $514 million from $693 million a year earlier, and net leverage held steady at 2.4 times trailing adjusted EBITDA.
Market Reaction and Sentiment
Shares of Emergent BioSolutions declined after the release, reflecting the revenue shortfall versus expectations and the reduced full-year outlook. Sentiment around the naloxone franchise has remained cautious amid new over-the-counter and generic competition that continues to affect pricing and volumes in U.S. channels. The guidance cut underscored concerns that near-term profitability will stay constrained, even though management pointed to disciplined cost control and ongoing debt reduction. Positive aspects such as solid cash flow conversion, lower gross debt, and upcoming restructuring savings were somewhat overshadowed by the softer top line.
Forward Outlook and Factors to Watch
Looking ahead, several areas stand out as important for the company's path. First is the pace of medical countermeasures contract activity. The firm completed a $24 million CYFENDUS contract modification during the quarter and supplied products to 13 countries, yet government procurement remains lumpy and timing can materially affect quarterly results.
Second, the naloxone franchise continues to represent a key risk area. Management anticipates ongoing competitive pressure on pricing and volume in the U.S. market, with Canadian branded NARCAN sales providing a partial offset. Pricing stability or further erosion will directly affect gross margins.
Finally, progress on restructuring and the balance sheet deserves attention. The August cost-reduction program is projected to generate about $40 million in annualized savings, with the full run-rate expected in 2027. A $75 million bond repurchase completed for $68 million in cash has already reduced interest expense and gross debt. Continued cash generation and further debt reduction will help indicate whether Emergent BioSolutions can rebuild profitability through 2027.
Enhancing Analysis with AI Tools
In my research process, I often rely on Tickeron's AI Screener to quickly filter healthcare and biotech names for technical patterns, fundamentals, and AI-driven signals. It helps surface comparable opportunities and confirm relative positioning without manual effort across thousands of securities. This approach keeps the focus on data-backed comparisons when evaluating names like Emergent BioSolutions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
EBS in -2.52% downward trend, falling for three consecutive days on October 21, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where EBS declined for three days, in 280 of 325 cases, the price declined further within the following month. The odds of a continued downward trend are 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
EBS broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on EBS as a result. In 68 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for EBS just turned positive on October 29, 2026. Looking at past instances where EBS's MACD turned positive, the stock continued to rise in 37 of 46 cases over the following month. The odds of a continued upward trend are 80%.
EBS moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where EBS advanced for three days, in 216 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 130 of 177 cases where EBS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.023) is normal, around the industry mean (8.329). P/E Ratio (-2.003) is within average values for comparable stocks, (-1.568). Projected Growth (PEG Ratio) (0.160) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.493) is also within normal values, averaging (178.797).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. EBS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EBS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of biopharmaceutical products
Industry PharmaceuticalsGeneric
Advertisement